53. Sjogren syndrome Clinical trials / Disease details

Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05087589 (ClinicalTrials.gov)	November 20, 2021	8/10/2021	Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome	Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjögren's Syndrome:a Prospective Observational Study	Primary Sjögren's Syndrome	Drug: Tofacitinib	Peking University People's Hospital	NULL	Recruiting	18 Years	N/A	All	10	Phase 2	China
2	NCT04496960 (ClinicalTrials.gov)	May 18, 2021	2/8/2020	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome	Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sj(SqrRoot)(Delta)Gren s Syndrome; a Phase Ib-IIa Placebo-controlled Clinical Trial and Associated Mechanistic Studies	Sjogren's Syndrome	Drug: tofacitinib;Other: Placebo	National Institute of Dental and Craniofacial Research (NIDCR)	NULL	Recruiting	18 Years	75 Years	All	30	Phase 1/Phase 2	United States